104 related articles for article (PubMed ID: 23107897)
1. Early development of secondary hyperparathyroidism following renal transplantation.
Isaksson E; Sterner G
Nephron Clin Pract; 2012; 121(1-2):c68-72. PubMed ID: 23107897
[TBL] [Abstract][Full Text] [Related]
2. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study.
Evenepoel P; Claes K; Kuypers D; Maes B; Bammens B; Vanrenterghem Y
Nephrol Dial Transplant; 2004 May; 19(5):1281-7. PubMed ID: 14993493
[TBL] [Abstract][Full Text] [Related]
3. Real-world doxercalciferol treatment in SHPT CKD stage 3 and 4: an analysis of change in iPTH and accordance to KDOQI recommendations.
Kumar N; Lindberg J; David K; Morris J; Menoyo J
Am J Nephrol; 2009; 29(2):71-8. PubMed ID: 18689981
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study.
Torregrosa JV; Morales E; Díaz JM; Crespo J; Bravo J; Gómez G; Gentil MÁ; Rodríguez Benot A; García MR; Jiménez VL; Gutiérrez Dalmau A; Jimeno L; Sáez MJ; Romero R; Gómez Alamillo C;
Nephrology (Carlton); 2014 Feb; 19(2):84-93. PubMed ID: 24428216
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet treatment for stable kidney transplantation patients with hypercalcemia due to persistent secondary hyperparathyroidism: a long-term follow-up.
Paschoalin RP; Torregrosa JV; Sánchez-Escuredo A; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Nov; 44(9):2588-9. PubMed ID: 23146463
[TBL] [Abstract][Full Text] [Related]
6. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
[TBL] [Abstract][Full Text] [Related]
7. Secondary hyperparathyroidism and risk factors in patients undergoing peritoneal dialysis in a tertiary hospital.
Suwan N
J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S101-5. PubMed ID: 22043575
[TBL] [Abstract][Full Text] [Related]
8. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival - a single-centre study in a stage 5 chronic kidney disease population.
Fotheringham J; Balasubramanian SP; Harrison B; Wilkie M
Nephron Clin Pract; 2011; 119(2):c113-20. PubMed ID: 21757948
[TBL] [Abstract][Full Text] [Related]
9. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
10. Long-term evolution of the mineral metabolism after renal transplantation: a prospective, single-center cohort study.
Van de Cauter J; Sennesael J; Haentjens P
Transplant Proc; 2011 Nov; 43(9):3470-5. PubMed ID: 22099822
[TBL] [Abstract][Full Text] [Related]
11. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
Bergua C; Torregrosa JV; Fuster D; Gutierrez-Dalmau A; Oppenheimer F; Campistol JM
Transplantation; 2008 Aug; 86(3):413-7. PubMed ID: 18698244
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
13. Intact parathyroid hormone levels in renal transplant patients with normal transplant function.
Bleskestad IH; Bergrem H; Leivestad T; Gøransson LG
Clin Transplant; 2011; 25(5):E566-70. PubMed ID: 21955131
[TBL] [Abstract][Full Text] [Related]
14. Evolution of secondary hyperparathyroidism after kidney transplantation in patients receiving cinacalcet on dialysis.
Torregrosa JV; Bergua C; Martinez de Osaba MJ; Oppenheimer F; Campistol JM
Transplant Proc; 2009; 41(6):2396-8. PubMed ID: 19715931
[TBL] [Abstract][Full Text] [Related]
15. The effects of mineral metabolism markers on renal transplant outcomes.
Marcén R; Jimenez S; Fernández A; Galeano C; Villafruela JJ; Burgos FJ; Quereda C
Transplant Proc; 2012 Nov; 44(9):2567-9. PubMed ID: 23146456
[TBL] [Abstract][Full Text] [Related]
16. Persistent hyperparathyroidism after kidney transplantation requiring parathyroidectomy.
Evenepoel P; Kuypers D; Maes B; Messiaen T; Vanrenterghem Y
Acta Otorhinolaryngol Belg; 2001; 55(2):177-86. PubMed ID: 11441477
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
18. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Nephrol Dial Transplant; 2011 Aug; 26(8):2691-5. PubMed ID: 21303965
[TBL] [Abstract][Full Text] [Related]
19. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
[TBL] [Abstract][Full Text] [Related]
20. Sleep disturbances before and after parathyroidectomy for secondary hyperparathyroidism.
Chou FF; Lee CH; Chen JB; Huang SC; Lee CT
Surgery; 2005 Apr; 137(4):426-30. PubMed ID: 15800490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
